Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol.

Randomised controlled trials (RCTs) on the management of COPD exacerbations evaluate heterogeneous outcomes, often omitting those that are clinically important and patient relevant. This limits their usability and comparability. A core outcome set (COS) is a consensus-based minimum set of clinically important outcomes that should be evaluated in all RCTs in specific areas of health care. We present the study protocol of the COS-AECOPD ERS Task Force, aiming to develop a COS for COPD exacerbation management, that could remedy these limitations. For the development of this COS we follow standard methodology recommended by the COMET initiative. A comprehensive list of outcomes is assembled through a methodological systematic review of the outcomes reported in relevant RCTs. Qualitative research with patients with COPD will also be conducted, aiming to identify additional outcomes that may be important to patients, but are not currently addressed in clinical research studies. Prioritisation of the core outcomes will be facilitated through an extensive, multi-stakeholder Delphi survey with a global reach. Selection will be finalised in an international, multi-stakeholder meeting. For every core outcome, we will recommend a specific measurement instrument and standardised time points for evaluation. Selection of instruments will be based on evidence-informed consensus. Our work will improve the quality, usability and comparability of future RCTs on the management of COPD exacerbations and, ultimately, the care of patients with COPD. Multi-stakeholder engagement and societal support by the European Respiratory Society will raise awareness and promote implementation of the COS

ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use

Structural, magnetic and catalytic properties of perovskite-type mixed oxides LaMn1-yCoyO3 (y = 0.0, 0.1, 0.3, 0.5, 0.7, 0.9, 1.0)

J. Mol. Catalysis A : Chemical, 2008, 282, 158-16

Efecto en las propiedades térmicas, magnéticas y catalíticas de la cobaltita dopada con 10 % Mn

Proceed. XXI SICAT, 2008. Proceedings de la conférenc

Lanthanum-based perovskites as catalysts for the ozonation of selected organic compounds

The ozonation of two model compounds (oxalic acid and dye C. I. Reactive Blue 5) was carried out in the presence of La containing perovskites prepared by the citrate method. With the exception of LaFe0.9Cu0.1O3, all samples are active in the catalytic ozonation of oxalic acid, some of them allowing fast degradation of the compound. The presence of lattice vacancies on the perovskites surface and tuning of oxidation ability by the B cation play a key role in oxalic acid removal. Sample LaCoO3 was considered the best catalyst in oxalic acid degradation; in addition to its high activity, no metal leaching was observed. Regarding colour removal from the dye solution, single ozonation was slightly more efficient than catalytic ozonation in the presence of LaCoO3. On the other hand, ozonation catalyzed by LaCoO3 improved the TOC removal, allowing almost complete mineralization of the solution after 3 h of reaction under the conditions tested.Fil: Orge, C. A.. Universidade do Porto. Faculdade de Engenharia. Departamento de Engenharia Química. Laboratório Associado LSRE/LCM. Laboratório de Catálise e Materiais; Portugal;Fil: Orfao, J. J. M.. Universidade do Porto. Faculdade de Engenharia. Departamento de Engenharia Química. Laboratório Associado LSRE/LCM. Laboratório de Catálise e Materiais; Portugal;Fil: Pereira, M. F. R.. Universidade do Porto. Faculdade de Engenharia. Departamento de Engenharia Química. Laboratório Associado LSRE/LCM. Laboratório de Catálise e Materiais; Portugal;Fil: Barbero, Bibiana Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico San Luis. Instituto de Investigaciones en Tecnología Química; Argentina;Fil: Cadus, Luis Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico San Luis. Instituto de Investigaciones en Tecnología Química; Argentina

ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritized for inclusion in the core outcome set through a two-round Delphi survey that was completed by 1,063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in 5 continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to (i) finalize the core outcome set and (ii) prioritize a single measurement instrument to be used for evaluating each of the prioritized outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for in all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, need for higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimize some of the selected measurement instruments. The panel did not consider the prioritized set of outcomes and associated measurement instruments burdensome for patients and health professionals to use